51 , 52 Our research identified a clear trend toward coagulation contact phase factors (FXI and FXII) as novel therapeutic targets.
← all excerpts
Balancing Beats and Bleeding: The Evolving Landscape of Atrial Fibrillation and Anticoagulation in the Past Two Decades.
1
—
—